KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Cash from Financing Activities (2018 - 2025)

ClearPoint Neuro's Cash from Financing Activities history spans 12 years, with the latest figure at $32.0 million for Q2 2025.

  • For Q2 2025, Cash from Financing Activities rose 19885.62% year-over-year to $32.0 million; the TTM value through Sep 2025 reached $30.7 million, up 386.0%, while the annual FY2024 figure was $6.2 million, 1990.88% up from the prior year.
  • Cash from Financing Activities for Q2 2025 was $32.0 million at ClearPoint Neuro, up from -$1.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $46.9 million in Q1 2021 and bottomed at -$10.1 million in Q3 2024.
  • The 5-year median for Cash from Financing Activities is $101500.0 (2021), against an average of $4.7 million.
  • The largest YoY upside for Cash from Financing Activities was 321160.0% in 2024 against a maximum downside of 10956.04% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $48000.0 in 2021, then surged by 362.5% to $222000.0 in 2022, then tumbled by 30.18% to $155000.0 in 2023, then crashed by 76.13% to $37000.0 in 2024, then skyrocketed by 86324.32% to $32.0 million in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Cash from Financing Activities are $32.0 million (Q2 2025), -$1.4 million (Q1 2025), and $37000.0 (Q4 2024).